Kyaw Zin Thein, MD is part of Comprehensive Cancer’s board certified and award-winning medical oncologist team that provides world-class cancer care in a supportive and caring environment. Dr. Thein also speaks Myanmar/Burmese.
EDUCATION
Kyaw Zin Thein, MD, completed his medical degree at the Institute of Medicine 1 in Yangon, Myanmar. He then spent three years as an internal medicine resident at Kingsbrook Jewish Medical Center in Brooklyn, New York where he served as a post-graduate year 3 chief resident. Following his residency, he completed two subspecialty fellowships; Oncologic Emergency Medicine and Investigational Cancer Therapeutics (phase 1) at the University of Texas MD Anderson Cancer Center in Houston, Texas, and Hematology and Medical Oncology fellowship training at Texas Tech University Health Sciences Center in Lubbock, Texas where he was elected to serve as a chief fellow in his third year.
AREAS OF SPECIAL INTEREST
Thrombosis, Head and Neck, Thyroid and rare cancers, Genitourinary Malignancies, Investigational Cancer Therapeutics including early phase clinical trials and phase 1 drug development.
EXPERIENCE
Prior to joining Comprehensive Cancer Centers, Dr. Thein was an Assistant Professor in the Division of Hematology and Medical Oncology at the Oregon Health and Science University (OHSU)/ Knight Cancer Institute (KCI). His main clinical interests include thrombosis, head and neck, thyroid, genitourinary and rare cancers. Dr. Thein also specializes in developing novel therapeutics as he co-led the early phase clinical trials (phase 1) program at OHSU, and his passion is to explore genetic-driven combinatorial strategies to tackle cancer. His goal is to improve the outcomes of the patients through the implementation of personalized and precision medicine approaches. During his time at OHSU, he served as a local site principal investigator and co-principal investigator on nearly 30 industry-initiated, multi-institutional trials. He also served as a member on the KCI’s Data and Safety Monitoring Committee where he ensured the compliance, quality, and safety of all interventional clinical trials.
PERSONAL
Dr. Thein loves to spend time with his family, play badminton, hike, read and write.
PATIENT PHILOSOPHY
His passion is to explore genetic-driven combinatorial strategies to tackle cancer and goal is to improve the outcomes of the patients through the implementation of personalized and precision medicine approaches. He believes the natural evolution of biomarker-driven trials is innovative and logical in the era where genetics is helping guide targeted therapy. He has advocated awareness of rare toxicities arising from newer targeted therapies and immunotherapies. He has also promoted health-related quality of life and symptom control/measures for his patients with cancer.
Treatment Center – Central Valley / Twain
3730 S. Eastern Avenue
Las Vegas, Nevada 89169
Tel: 702-952-3400
Fax: 702.952.3461
BOARD CERTIFIED
American Board of Medical Oncology
American Board of Hematology
American Board of Internal Medicine
MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS
American Society of Clinical Oncology
European Society for Medical Oncology
American Association for Cancer Research
Society for Immunotherapy of Cancer
International Association for the Study of Lung Cancer
American Society of Hematology
European Hematology Association
International Society on Thrombosis and Hemostasis
American Medical Association
American College of Physicians
PUBLICATIONS
Dr. Thein has published more than 50 peer-reviewed articles and book chapters in various publications including CA: A Cancer Journal for Clinicians, Cancer Discovery, Trends in Cancer, Nature Communications, Annual Review, JCO Precision Oncology, Experimental Hematology & Oncology and Investigational New Drugs. He has also presented more than 150 oral and poster presentations at national and international conferences including American Society of Hematology, European Society for Medical Oncology, American Society of Clinical Oncology, International Association for the Study of Lung Cancer, British Society for Hematology, American Thoracic Society and National Comprehensive Cancer Network, among others.
Low, G.M.I., Thein, K.Z., Shah, S., Chandra, R.A., Li, R.J. (2022). ‘Novel Multidisciplinary Paradigms: Surgery/Radiation, Immunotherapy, Organ Preservation’. In: Chandra, R.A., Li, R.J. (eds) Multidisciplinary Management of Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-05973-5_2
Thein, K.Z., Thawani, R., Kummar, S. ‘Combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: progress, pitfalls and promises’. In: Yap, T.A., Shapiro, G.I. (eds) Targeting the DNA Damage Response for Cancer Therapy. Springer, In press.
Thawani R, Kim MS, Arastu A, Feng Z, West MT, Taflin NF, Thein KZ, Li R, Geltzeiler M, Lee N, Fuller CD, Grandis JR, Floudas CS, Heinrich MC, Hanna E, Chandra RA. ‘The Contemporary Management of Cancers of the Sinonasal Tract in Adults’. CA Cancer J Clin. 2022 Aug 2. doi: 10.3322/caac.21752. Online ahead of print. PMID: 35916666
Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. ‘Dual EGFR Blockade with Cetuximab and Erlotinib combined with Anti-VEGF Antibody Bevacizumab in Advanced solid tumors: A Phase 1 dose escalation triplet combination trial’. Exp Hematol Oncol. 2020 Apr 20;9:7. doi: 10.1186/s40164-020-00159-1. eCollection 2020. PMID: 32337094
Kyaw Z. Thein, Thura Htut, Somedeb Ball, Sriman Swarup, Anita Sultan, Thein H. Oo. ‘Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: A systematic review and meta- analysis of randomized controlled trials’. Breast Cancer Res Treat. 2020 Sep;183(2):479-487. doi: 10.1007/s10549-020-05783-3. Epub 2020 Jul 9. PMID: 32647939
Kyaw Z. Thein, Amadeo B. Biter, and David S. Hong. ‘Therapeutics Targeting Mutant KRAS’. Annu Rev Med. 2021 Jan 27;72:349-364. doi: 10.1146/annurev-med-080819-033145. Epub 2020 Nov 2. PMID: 33138715
Piha-Paul SA, Thein KZ, De Souza P, Kefford R, Gangadhar T, Smith C, Schuster S, Zamboni WC, Dees CE, Markman B. ‘First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies’. Invest New Drugs. 2021 Feb 16. doi: 10.1007/s10637-021-01081-x. Online ahead of print. PMID: 33594602
Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Zarifa A, Shah J, Milton DR, Bean S, McQuinn L, Gong J, Colen R, Carter BW, Subbiah V, Ogbonna DC, Pant S, Meric-Bernstam F, Naing A. ‘Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study’. Invest New Drugs. 2021 Apr 28. doi: 10.1007/s10637-021-01119-0. PMID: 33909232
Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. ‘9p21 Loss Confers a Cold Tumor Immune Microenvironment and Primary Resistance to Immune Checkpoint Therapy’. Nat Commun. 2021 Sep 23;12(1):5606. doi: 10.1038/s41467-021-25894-9. PMID: 34556668
Kyaw Z Thein, Steven Lemery, Shivaani Kummar. ‘Tissue Agnostic Drug Development: A New Path to Drug Approval’. Cancer Discov. 2021 Sep;11(9):2139-2144. doi: 10.1158/2159-8290.CD-21-0554. PMID: 34479971
Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. ‘Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumors: Results of a single-center, multi-arm phase Ib study’. Invest New Drugs. 2021 Sep 25. doi: 10.1007/s10637-021-01188-1. Online ahead of print. PMID: 34562230
Kyaw Z Thein, Vamsidhar Velcheti, Blaine. H. M. Mooers, J Wu, Vivek Subbiah. ‘Precision therapy for RET-altered cancers with RET inhibitors’. Trends Cancer. 2021 Dec;7(12):1074-1088. doi: 10.1016/j.trecan.2021.07.003. Epub 2021 Aug 12. PMID: 34391699
Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. ‘Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors’. Exp Hematol Oncol. 2021 Dec 29;10(1):59. doi: 10.1186/s40164-021-00251-0. PMID: 34965890
Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. ‘Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers’. JCO Precis Oncol. 2022 Feb;6:e2100267. doi: 10.1200/PO.21.00267. PMID: 35108036
Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. ‘Identification of KRASG12C mutations in circulating tumor DNA from 80,911 patients with cancer’. JCO Precis Oncol. 2022 Jul;6:e2100547. doi: 10.1200/PO.21.00547. PMID: 35862868
This form is not intended for current patients of Comprehensive. If you are a patient, please contact your treatment center with any questions.
If you are experiencing a medical emergency, please call 911 immediately or go to the nearest emergency room. This form is not intended for emergencies.
